Literature DB >> 22583404

Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs.

Stephen H Safe1, Paul L Prather, Lisa K Brents, Gayathri Chadalapaka, Indira Jutooru.   

Abstract

Triterpenoids such as betulinic acid (BA) and synthetic analogs of oleanolic acid [2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)] and glycyrrhetinic acid [2-cyano-3,11-dioxo-18β-oleana-1,12-dien-30-oc acid (CDODA)] are potent anticancer agents that exhibit antiproliferative, antiangiogenic, anti-inflammatory and pro-apoptotic activities. Although their effects on multiple pathways have been reported, unifying mechanisms of action have not been reported. Studies in this laboratory have now demonstrated that several triterpenoids including BA and some derivatives, celastrol, methyl ursolate, β-boswellic acid derivatives, and the synthetic analogs CDDO, CDODA and their esters decreased expression of specificity protein (Sp) transcription factors and several pro-oncogenic Sp-regulated genes in multiple cancer cell lines. The mechanisms of this response are both compound- and cell context-dependent and include activation of both proteasome-dependent and -independent pathways. Triterpenoid-mediated induction of reactive oxygen species (ROS) has now been characterized as an important proteasome-independent pathway for downregulation of Sp transcription factors. ROS decreases expression of microRNA-27a (miR-27a) and miR-20a/miR-17-5p and this results in the induction of the transcriptional "Sp-repressors" ZBTB10 and ZBTB4, respectively, which in turn downregulate Sp and Sp-regulated genes. Triterpenoids also activate or deactive nuclear receptors and G-protein coupled receptors, and these pathways contribute to their antitumorigenic activity and may also play a role in targeting Sp1, Sp3 and Sp4 which are highly overexpressed in multiple cancers and appear to be important for maintaining the cancer phenotype.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22583404      PMCID: PMC3532564          DOI: 10.2174/187152012803833099

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  102 in total

Review 1.  Mitochondrion as a novel target of anticancer chemotherapy.

Authors:  P Costantini; E Jacotot; D Decaudin; G Kroemer
Journal:  J Natl Cancer Inst       Date:  2000-07-05       Impact factor: 13.506

2.  Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells.

Authors:  Satya S Pathi; Ping Lei; Sandeep Sreevalsan; Gayathri Chadalapaka; Indira Jutooru; Stephen Safe
Journal:  Nutr Cancer       Date:  2011-09-15       Impact factor: 2.900

Review 3.  Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis.

Authors:  L Fajas; M B Debril; J Auwerx
Journal:  J Mol Endocrinol       Date:  2001-08       Impact factor: 5.098

4.  Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells.

Authors:  Gayathri Chadalapaka; Indira Jutooru; Robert Burghardt; Stephen Safe
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

5.  Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives.

Authors:  Gayathri Chadalapaka; Indira Jutooru; Alan McAlees; Tom Stefanac; Stephen Safe
Journal:  Bioorg Med Chem Lett       Date:  2008-03-14       Impact factor: 2.823

6.  PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.

Authors:  Yoko Tabe; Marina Konopleva; Yutaka Kondo; Rooha Contractor; Twee Tsao; Sergej Konoplev; Yuexi Shi; Xiaoyang Ling; Julie C Watt; Yuko Tsutsumi-Ishii; Akimichi Ohsaka; Isao Nagaoka; Jean-Pierre J Issa; Scott C Kogan; Michael Andreeff
Journal:  Cancer Biol Ther       Date:  2007-09-04       Impact factor: 4.742

Review 7.  Targeting mitochondria.

Authors:  Adam T Hoye; Jennifer E Davoren; Peter Wipf; Mitchell P Fink; Valerian E Kagan
Journal:  Acc Chem Res       Date:  2008-01       Impact factor: 22.384

8.  Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression.

Authors:  Bohuslav Melichar; Marina Konopleva; Wei Hu; Karolina Melicharova; Michael Andreeff; Ralph S Freedman
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

9.  Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.

Authors:  Santhi Konduri; Jimmie Colon; Cheryl H Baker; Stephen Safe; James L Abbruzzese; Ala Abudayyeh; Md Riyaz Basha; Maen Abdelrahim
Journal:  Mol Cancer Ther       Date:  2009-03-03       Impact factor: 6.261

Review 10.  Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid.

Authors:  Riyaz Basha; Cheryl H Baker; Umesh T Sankpal; Sarfraz Ahmad; Stephen Safe; James L Abbruzzese; Maen Abdelrahim
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01
View more
  9 in total

1.  Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives.

Authors:  Nisha R Parikh; Animesh Mandal; Deepak Bhatia; Kodappully Sivaraman Siveen; Gautam Sethi; Anupam Bishayee
Journal:  Phytochem Rev       Date:  2014-12       Impact factor: 5.374

2.  MicroRNA-Specificity Protein (Sp) Transcription Factor Interactions and Significance in Carcinogenesis.

Authors:  Stephen Safe
Journal:  Curr Pharmacol Rep       Date:  2015-01-11

3.  The dual induction of apoptosis and autophagy by SZC014, a synthetic oleanolic acid derivative, in gastric cancer cells via NF-κB pathway.

Authors:  Li Xiao Rui; Song Yu Shu; Wu Jing Jun; Chen Zi Mo; Sun Zheng Wu; Liu Shu Min; Lin Yuan; Peng Jin Yong; Song Zhi Cheng; Wang Shi Sheng; Tang Ze Yao
Journal:  Tumour Biol       Date:  2015-11-07

4.  The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non-Small Cell Lung Cancer.

Authors:  Ebony Nottingham; Vasanthakumar Sekar; Arindam Mondal; Stephen Safe; Arun K Rishi; Mandip Singh
Journal:  J Pharm Sci       Date:  2020-01-15       Impact factor: 3.534

5.  Crystal structure of betulinic acid methanol monosolvate.

Authors:  Wei Tang; Neng-Hua Chen; Guo-Qiang Li; Guo-Cai Wang; Yao-Lan Li
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-11-08

Review 6.  A Review of the Potential of Phytochemicals from Prunus africana (Hook f.) Kalkman Stem Bark for Chemoprevention and Chemotherapy of Prostate Cancer.

Authors:  Richard Komakech; Youngmin Kang; Jun-Hwan Lee; Francis Omujal
Journal:  Evid Based Complement Alternat Med       Date:  2017-02-13       Impact factor: 2.629

Review 7.  Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.

Authors:  Beate C Litzenburger; Powel H Brown
Journal:  Curr Breast Cancer Rep       Date:  2014

8.  Discovery of triterpenoids as reversible inhibitors of α/β-hydrolase domain containing 12 (ABHD12).

Authors:  Teija Parkkari; Raisa Haavikko; Tuomo Laitinen; Dina Navia-Paldanius; Roosa Rytilahti; Miia Vaara; Marko Lehtonen; Sami Alakurtti; Jari Yli-Kauhaluoma; Tapio Nevalainen; Juha R Savinainen; Jarmo T Laitinen
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

9.  Anticancer Activities of the Quinone-Methide Triterpenes Maytenin and 22-β-hydroxymaytenin Obtained from Cultivated Maytenus ilicifolia Roots Associated with Down-Regulation of miRNA-27a and miR-20a/miR-17-5p.

Authors:  Camila Hernandes; Lucyene Miguita; Romario Oliveira de Sales; Elisangela de Paula Silva; Pedro Omori Ribeiro de Mendonça; Bruna Lorencini da Silva; Maria de Fatima Guarizo Klingbeil; Monica Beatriz Mathor; Erika Bevilaqua Rangel; Luciana Cavalheiro Marti; Juliana da Silva Coppede; Fabio Daumas Nunes; Ana Maria Soares Pereira; Patricia Severino
Journal:  Molecules       Date:  2020-02-10       Impact factor: 4.927

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.